Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of daratumumab in combination with thalidomide and dexamethasone in relapsed or refractory myeloma
KCT0004202Phase 2Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Seoul National University Hospital. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0004202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004202.